Medication Discontinuation Following Transurethral Prostatectomy: an Unrecognized Effectiveness Measure?
Rebecca A CampbellBradley C GillPublished in: Current urology reports (2020)
Rates of BPH/LUTS medication use after transurethral resection of the prostate varied from 15% to 55%, and discontinuation rates were 54-95% across medications and follow-up periods. For laser prostatectomy, approximately 18% of patients continued medications postoperatively and discontinuation rates ranged from 53% to 75%. Minimal data on holmium laser enucleation existed. For reference, medication discontinuation rates after transurethral needle ablation or microwave therapy were only 15-28%. No recommendations or best practices inform the use of medical therapy following BPH surgery. Rates of BPH/LUTS medication use following transurethral prostatectomy are considerable.
Keyphrases
- benign prostatic hyperplasia
- lower urinary tract symptoms
- healthcare
- randomized controlled trial
- primary care
- end stage renal disease
- newly diagnosed
- emergency department
- prostate cancer
- machine learning
- peritoneal dialysis
- coronary artery bypass
- mass spectrometry
- acute coronary syndrome
- patient reported outcomes
- atrial fibrillation